12:00 AM
Mar 18, 2013
 |  BC Week In Review  |  Clinical News  |  Regulatory

CMX001 regulatory update

FDA granted Fast Track designation to Chimerix's CMX001 to prevent cytomegalovirus (CMV) infection. This year, Chimerix plans to start the Phase III SUPPRESS...

Read the full 92 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >